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I. INTRODUCTION 
Medical progress in America is driven by innovation. Nevertheless, 
throughout American history, many have died as a result of human 
experimentation performed under the guise of innovation. Although the 
Food and Drug Administration (“FDA”) can easily regulate drugs, 
regulating physicians is a much more daunting task. Under current law, a 
doctor may try any treatment, regardless of whether it is objectively 
reasonable, as long as the doctor first obtains the patient’s informed 
consent.1 The purpose of this Comment is to demonstrate that a patient’s 
informed consent is an inadequate protection from harm and a new rule, 
the reasonable innovation rule, must be codified. Codification of the 
reasonable innovation rule will balance the dual goals of medical 
innovation and patient protection. 
First, a preliminary explanation of the reasonable innovation rule is 
required. Ordinarily, customary care, the standard practice established in 
the medical field in any given jurisdiction, meets the needs of most 
1. K.H. Satyanarayana Rao, Informed Consent: An Ethical Obligation or Legal
Compulsion?, 1 J. CUTANEOUS & AESTHETIC SURGERY 33, 33 (2008), available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840885/. Informed consent hinges on the ethical 
principle of autonomy, which is the patient’s right to decide what happens to his or her body. Id. 
Informed consent can either be express or implied. Id.; see also Bryan Murray, Informed Consent: 
What Must a Physician Disclose to a Patient?, 14 VIRTUAL MENTOR 563, 563 (2012), available at 
http://virtualmentor.ama-assn.org/2012/07/hlaw1-1207.html. Prior to obtaining informed consent, 
physicians must explain any risks and benefits, as well as any information a reasonable person 
would find important to the decision-making process. Id. 
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patients.2 Under the reasonable innovation rule, if customary care is 
unlikely to provide adequate treatment for one particular patient, a 
doctor may innovate to meet the patient’s unique needs.3 The rule 
demands that the innovative procedure be thoroughly researched before 
being implemented.4 In other words, a physician may not implement any 
treatment, only one that is reasonable. “Reasonableness” is a higher 
standard than “informed consent” because it mandates a shared 
responsibility between doctor and patient to engage only in treatments 
that are considered objectively reasonable. This shifts some of the 
burden currently pressuring patients to consent to risky, inadequately 
researched procedures suggested by their physicians.5 
Part II of this Comment will examine the history of human 
experimentation and how the current regime of experimenting developed 
then explore the gap between experimentation approved by an 
Institutional Review Board (“IRB”)6 and FDA oversight. Part III will 
consider the competing interests of individual patient protection and 
medical innovation in general and whether informed consent 
appropriately balances those interests. Part IV will evaluate the 
inadequacies of current reliance on informed consent by using two case 
studies, both involving novel microbial procedures, and discuss how 
codification of the reasonable innovation rule would address those 
inadequacies. 
The two case studies involve (1) fecal microbiota transplants, which 
have been highly successful,7 and (2) bacterial transplants performed in 
2. 1 STEVEN E. PEGALIS, AMERICAN LAW OF MEDICAL MALPRACTICE § 3.3 (3d ed. rev.
2014). 
3. Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 76 (Ind. 1978). 
4. Id.
5. Nancy M. Kettle, Informed Consent: Its Origins, Purpose, Problems, and Limits 64-65
(Aug. 9, 2002) (unpublished Master thesis, University of South Florida), available at 
http://scholarcommons.usf.edu/cgi/viewcontent.cgi?article=2522&context=etd. 
6. Institutional Review Boards Frequently Asked Questions, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/regulatoryinformation/guidances/ucm126420.htm (last updated June 25, 2014) 
[hereinafter IRB FAQs]. “Under FDA regulations, an IRB is an appropriately constituted group that 
has been formally designated to review and monitor biomedical research involving human subjects. 
In accordance with FDA regulations, an IRB has the authority to approve, require modifications in 
(to secure approval), or disapprove research. This group review serves an important role in the 
protection of the rights and welfare of human research subjects. The purpose of IRB review is to 
assure, both in advance and by periodic review, that appropriate steps are taken to protect the rights 
and welfare of humans participating as subjects in the research. To accomplish this purpose, IRBs 
use a group process to review research protocols and related materials (e.g., informed consent 
documents and investigator brochures) to ensure protection of the rights and welfare of human 
subjects of research.” Id. 
7. Maryn McKenna, Swapping Germs: Should Fecal Transplants Become Routine for
Debilitating Diarrhea?, SCI. AM. (Dec. 6, 2011), http://www.scientificamerican.com/
3
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an attempt to cure brain cancer, which had deadly consequences.8 In 
both cases, as with human experimentation as a whole, informed consent 
played a crucial role. These cases, however, also raise the question 
whether consent should bar recovery. Vulnerable, ill patients may 
consent to dangerous experiments out of desperation. The inadequacies 
of informed consent will be discussed with this in mind. 
Ultimately, this Comment will argue that the common law 
reasonable innovation rule must be codified to protect vulnerable 
patients who are willing to try anything. Current oversight and 
regulation of physicians who implement novel treatments on a regular 
basis do not offer enough protection to the desperate patient. It is time 
for the FDA to intervene in our current “wild west” system where 
physicians are free to deviate from common practice and implement 
novel and even dangerous procedures as long as they obtain patients’ 
informed consent. 
The FDA must take action by incorporating the reasonable 
innovation rule into federal regulations instead of leaving it hidden in 
case law. This will set a minimum standard for physicians who wish to 
integrate novel treatments into everyday practice. Codifying the rule will 
not unreasonably restrict innovation because physicians will be able to 
try new procedures that meet patients’ unique needs, provided the 
procedures are well researched and reasonable. 
II. REGULATION IN THE UNITED STATES: A BACKGROUND
A. The History of Human Experimentation Without Regulation 
America has a dark history of human experimentation, even within 
the past 100 years.9 This Comment maintains it is futile to believe that 
vulnerable populations can always provide true informed consent for 
treatment using experimental procedures. It asserts, instead, that the 
obtaining of informed consent for experimental treatment from certain 
patients, including those who are terminally ill, near death, and for 
whom approved treatments have failed, is problematic. The practice, in 
fact, provides disconcerting parallels, though on an individual basis, to 
article.cfm?id=swapping-germs. 
8. See Marjie Lundstrom, UC Davis Surgeons Resign After Bacteria-in-Brain Dispute,
SACRAMENTO BEE, http://www.sacbee.com/2013/08/25/5678851/uc-davis-surgeons-resign-
after.html (updated Oct. 6, 2014, 2:38 PM). 
9. Mike Stobbe, Ugly Past of US Human Experiments Uncovered, NBC NEWS,
http://www.nbcnews.com/id/41811750/ns/health-health_care/#.UtLxOfRDua8 (last updated Feb. 
27, 2011, 6:14 PM). 
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prior human experimentation that we now consider unethical, 
regrettable, and of little benefit to the subjects involved. 
Several case studies regarding medical research undertaken by 
American researchers involving human subjects demonstrate how 
vulnerable individual patients can be and support this Comment’s thesis 
that regulation is essential to protect patients even from well-intentioned 
researchers. For instance, in 1932, the Public Health Service began an 
experiment called the “Tuskegee Study of Untreated Syphilis in the 
Negro Male.”10 The purpose of this study was to determine how syphilis 
affected African Americans as opposed to Caucasians.11 The theory of 
the experiment was that Caucasians experienced more neurological 
complications from syphilis while African Americans experienced more 
cardiovascular complications.12 How the results of the study would be 
used in clinical treatment remains unclear.13 
This study had several problems. First, it lacked adequate informed 
consent.14 Rather than revealing the true purpose of the experiment (to 
record the “natural history of syphilis in Blacks”),15 the researchers 
informed the 600 participants, who were all black men, that they were 
being treated for “bad blood.”16 “Bad blood” was a colloquial expression 
used to describe a variety of illnesses such as anemia, fatigue, and 
syphilis.17 The researchers did not disclose the study’s true purpose 
because they wanted to ensure cooperation.18 Furthermore, although no 
proven treatments for the disease existed when the study commenced, 
penicillin was found to be an effective treatment in 1947.19 Nevertheless, 
the researchers withheld this treatment from the participants.20 This 
study, which was projected to last a short six months, actually continued 
for forty years.21 As a result, 28 men died from syphilis, 100 men died 
10. The Tuskegee Timeline, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/tuskegee/timeline.htm (last updated Sep. 24, 2013). 
11. Borgna Brunner, The Tuskegee Syphilis Experiment, INFOPLEASE (2007),
http://www.infoplease.com/spot/bhmtuskegee1.html. 
12. Id.
13. Id.
14. Id.
15. About the USPHS Syphilis Study, TUSKEGEE UNIV., http://www.tuskegee.edu/about_us/
centers_of_excellence/bioethics_center/about_the_usphs_syphilis_study.aspx (last visited Jan. 7, 
2014). 
16. Id.
17. Id.
18. Brunner, supra note 11.
19. The Tuskegee Timeline, supra note 10.
20. Id.
21. Id.
5
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from related complications, 40 men infected their wives, and 19 of their 
children were born with congenital syphilis.22 
Another flagrant example of human experimentation involved the 
discovery and development of penicillin in the mid-1900s.23 From 1946 
to 1948, American public health doctors deliberately infected over 1,600 
Guatemalans aged 10 to 72—prison inmates, children, mental patients, 
female prostitutes, and soldiers—with venereal diseases in order to test 
the efficacy of penicillin in treating or preventing sexually transmitted 
diseases.24 In total, 696 were infected with syphilis, 772 with gonorrhea, 
and 142 with chancres.25 After subjects contracted the disease, they were 
given penicillin.26 Not surprisingly, the research failed to yield any 
medically useful information.27 The study was well hidden and came to 
light only in 2011 when it was revealed that 83 of these patients died as 
a result of the experiment.28 
During the same time, American doctors were performing another 
human experiment in Guatemala.29 They injected seven women, 
residents of a Guatemalan insane asylum, with syphilis in the back of the 
skull.30 The researchers hoped the syphilis infection would cure epilepsy, 
but instead, the women contracted bacterial meningitis, probably due to 
unsterilized injection needles.31 
The 1940s through 1950s saw massive growth in the 
pharmaceutical industry, and as a result, the government and private 
22. Brunner, supra note 11.
23. Donald G. McNeil, Jr., U.S. Apologizes for Syphilis Tests in Guatemala, N.Y. TIMES
(Oct.1, 2010), http://www.nytimes.com/2010/10/02/health/research/02infect.html?_r=0; see also 
Mariano Castillo, Guatemalans to File Appeal Over STD Experiments, CNN (June 15, 2012), 
http://www.cnn.com/2012/06/15/us/guatemala-std-experiments/index.html. 
24. Castillo, supra note 23. Shockingly, “American tax dollars, through the National
Institutes of Health, even paid for syphilis-infected prostitutes to sleep with prisoners, since 
Guatemalan prisons allowed such visits. When the prostitutes did not succeed in infecting the men, 
some prisoners had the bacteria poured onto scrapes made on their penises, faces or arms, and in 
some cases it was injected by spinal puncture.” McNeil, supra note 23; see also Kara Rogers, 
Guatemala Syphilis Experiment, ENCYCLOPÆDIA BRITANNICA, http://www.britannica.com/
EBchecked/topic/1805220/Guatemala-syphilis-experiment (last visited Feb. 21, 2014). 
25. Castillo, supra note 23.
26. Id.
27. Shocking New Details of US STD Experiments in Guatemala, ASSOCIATED PRESS, Aug.
30, 2011, available at http://www.theguardian.com/world/2011/aug/30/guatemala-experiments. 
28. Id.; see also Susan Donaldson James, Syphilis Experiments Shock, But So Do Third
World Drug Trials, ABC NEWS (Aug. 30, 2011), http://abcnews.go.com/Health/guatemala-syphilis-
experiments-shock-us-drug-trials-exploit/story?id=14414902. 
29. Id.
30. Id.
31. Id.
6
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corporations began to fund prisoner experimentation.32 “By the 1960s, at 
least half the states allowed prisoners to be used as medical guinea 
pigs.”33 It was not until 1978 that the FDA stepped in to regulate human 
experiments conducted on prisoners.34 These examples of horrific 
medical research performed on human subjects demonstrate that strict 
regulations designed to protect people who are participating in a study, 
or any type of experimental treatment, are necessary. 
B. Experimental Treatment and the FDA: The Space Between 
This Comment argues that, while strong statutory protections are in 
place for human subjects, oversight by the FDA is lacking. Because of 
the gaps in oversight, it is inevitable that some vulnerable patients are 
being subjected to inappropriate experimental treatment. First, a 
preliminary explanation of the origin of statutory protections is required. 
Next, the intricacies of the FDA drug approval process will be detailed, 
and the FDA’s control over IRBs will be scrutinized. Finally, because of 
a lack of oversight of IRBs, patients have relied on tort law and medical 
malpractice actions to encourage physicians to use appropriate care in 
suggesting experimental treatments. Thus, a brief explanation of medical 
malpractice is provided for understanding the basis of those claims. 
1. The Origin of Statutory Protections
Most of the basic regulations concerning human subject research 
come from the Department of Health and Human Services (“DHHS”).35 
The DHHS is a cabinet-level department of the federal government that 
includes 11 agencies.36 The FDA, one of the DHHS agencies, is tasked 
32. Stobbe, supra note 9.
33. Id. “Holmesburg Prison in Philadelphia made extensive use of inmates for medical
experiments. Some of the victims are still around to talk about it. Edward ‘Yusef’ Anthony, featured 
in a book about the studies, says he agreed to have a layer of skin peeled off his back, which was 
coated with searing chemicals to test a drug. He did that for money to buy cigarettes in prison.” Id. 
34. Prisoners in Clinical Trials, FIRST CLINICAL RES. (Nov. 21, 2007),
http://firstclinical.com/fda-
gcp/?show=2007/RE%20Prisoners%20in%20clinical%20trials&format=fulllist. 
35. Regulations, DEPT. OF HEALTH & HUMAN SERV., http://www.hhs.gov/
ohrp/humansubjects/ (last visited Jan. 10, 2014). “In the United States, a series of highly publicized 
abuses in research led to the enactment of the 1974 National Research Act (Public Law 93-348), 
which created the National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research. One of the charges to the National Commission was to identify the basic 
ethical principles that should underlie the conduct of biomedical and behavioral research involving 
human subjects and to develop guidelines to assure that such research is conducted in accordance 
with those principles.” Id. 
36. About HHS, U.S. DEPT. OF HEALTH & HUMAN SERV., http://www.hhs.gov/about/ (last
7
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with regulating “clinical investigations of products under its jurisdiction, 
such as drugs, biological products, and medical devices.”37 The FDA, 
although under the DHHS umbrella, has its own specific rules for human 
subject research to protect participants in the clinical trials of new drugs 
and devices.38 Any variation between DHHS and FDA rules reflect 
differences in the statutory scope or requirements.39 
2. The Drug Approval Process
In response to a push for “legally mandated quality and identity 
standards for food, prohibition of false therapeutic claims for drugs, 
coverage of cosmetics and medical devices, clarification of the FDA’s 
right to conduct factory inspections, and control of product advertising,” 
Congress passed the 1938 Food, Drug, and Cosmetic Act (“FDCA”).40 
One of the most important provisions of this law was a mandate that 
drug manufacturers prove to the FDA that a drug is safe before it can be 
sold on the market.41 This pre-market approval process forever changed 
the way that drugs are regulated in the United States.42 
The FDA drug approval process for both prescription and over-the-
counter drugs involves several steps. First, after obtaining promising 
clinical data, a drug manufacturer must apply for an Investigational New 
Drug Application (“IND”) from the FDA’s Center for Drug Evaluation 
and Research.43 After submitting an IND, a manufacturer must wait 30 
days before beginning clinical trials44 to allow the FDA to research and 
review the prospective study.45 “If [the] FDA finds a problem, it can 
revised Oct. 6, 2014). 
37. Regulations, supra note 35.
38. Comparison of FDA and HHS Human Subject Protection Regulations, U.S. FOOD &
DRUG ADMIN., http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/
EducationalMaterials/ucm112910.htm (last updated Mar. 10, 2009). 
39. Id.
40. The 1938 Food, Drug, and Cosmetic Act, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/aboutFDA/WhatWeDo/History/origin/ucm054826.htm (last updated Sep. 24, 
2012). 
41. Id.
42. Id.
43. How Drugs are Developed and Approved, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/de
fault.htm (last updated Feb. 13, 2014). The Center for Drug Evaluation and Research “is the largest 
of FDA’s five centers. It has responsibility for both prescription and nonprescription or over-the-
counter (OTC) drugs. The other four FDA centers have responsibility for medical and radiological 
devices, food, and cosmetics, biologics, and veterinary drugs.” Id. 
44. “Clinical trials are experiments that use human subjects to see whether a drug is effective,
and what side effects it may cause.” Id. 
45. Id.
8
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order a ‘clinical hold’ to delay an investigation, or interrupt a clinical 
trial if problems occur during the study.”46 After clinical trials are 
complete and the manufacturer has determined that enough evidence 
exists to meet the FDA’s standards, the manufacturer must then submit a 
New Drug Approval Application (“NDA”).47 The NDA is a detailed 
application containing information such as “manufacturing 
specifications, stability and bioavailablility data, method of analysis of 
each of the dosage forms the sponsor intends to market, packaging and 
labeling for both physician and consumer, and the results of any 
additional toxicological studies not already submitted.”48 Only after the 
NDA is approved may the drug be placed on the market.49 
3. Regulation of Institutional Review Boards
The FDA has the power to regulate not only drugs and devices but 
also IRBs. “An IRB is an appropriately constituted group that has been 
formally designated to review and monitor biomedical research 
involving human subjects.”50 Under current law, the FDA requires 
IRBs51 to “review and monitor biomedical research involving human 
subjects.”52 Each IRB that oversees FDA-regulated studies must register 
with the FDA.53 All IRBs must assure that each human subject has given 
informed consent prior to commencement of the study.54 
46. Id.
47. Id.
48. Id.
49. Id.
50. See IRB FAQs, supra note 6.
51. For a description of IRBs, see id.
52. See id.
53. Id.
54. Id. “The fundamental purpose of IRB review of informed consent is to assure that the
rights and welfare of subjects are protected. A signed informed consent document is evidence that 
the document has been provided to a prospective subject (and presumably, explained) and that the 
subject has agreed to participate in the research. IRB review of informed consent documents also 
ensures that the institution has complied with applicable regulations.” Id. The FDA sets out the 
following criteria for IRB approval of research in 21 C.F.R. § 56.111 (2013): 
(a) In order to approve research covered by these regulations the IRB shall 
determine that all of the following requirements are satisfied: 
(1) Risks to subjects are minimized: (i) By using procedures which are 
consistent with sound research design and which do not unnecessarily expose 
subjects to risk, and (ii) whenever appropriate, by using procedures already 
being performed on the subjects for diagnostic or treatment purposes. 
(2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to 
subjects, and the importance of the knowledge that may be expected to result. 
In evaluating risks and benefits, the IRB should consider only those risks and 
benefits that may result from the research (as distinguished from risks and 
9
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IRBs have incurred a lot of criticism through the years, but perhaps 
the most serious concern is the FDA’s lack of oversight.55 In 2007, the 
Office of the Inspector General stated that the FDA’s oversight of IRB 
clinical trials was “weak, disorganized, and thus unable to ensure the 
safety of clinical research participants.”56 The Office of the Inspector 
General further noted the FDA could not possibly supervise all clinical 
trials or IRBs tasked with overseeing the research involved in the trials 
benefits of therapies that subjects would receive even if not participating in the 
research). The IRB should not consider possible long-range effects of applying 
knowledge gained in the research (for example, the possible effects of the 
research on public policy) as among those research risks that fall within the 
purview of its responsibility. 
(3) Selection of subjects is equitable. In making this assessment the IRB should 
take into account the purposes of the research and the setting in which the 
research will be conducted and should be particularly cognizant of the special 
problems of research involving vulnerable populations, such as children, 
prisoners, pregnant women, handicapped, or mentally disabled persons, or 
economically or educationally disadvantaged persons. 
(4) Informed consent will be sought from each prospective subject or the 
subject’s legally authorized representative, in accordance with and to the extent 
required by part 50. 
(5) Informed consent will be appropriately documented, in accordance with and 
to the extent required by 50.27. 
(6) Where appropriate, the research plan makes adequate provision for 
monitoring the data collected to ensure the safety of subjects. 
(7) Where appropriate, there are adequate provisions to protect the privacy of 
subjects and to maintain the confidentiality of data. 
(b) When some or all of the subjects, such as children, prisoners, pregnant 
women, handicapped, or mentally disabled persons, or economically or 
educationally disadvantaged persons, are likely to be vulnerable to coercion or 
undue influence additional safeguards have been included in the study to 
protect the rights and welfare of these subjects. 
(c) In order to approve research in which some or all of the subjects are 
children, an IRB must determine that all research is in compliance with part 50, 
subpart D of this chapter. 
55. David A. Hyman, Institutional Review Boards: Is This the Least Worst We Can Do?, 101
NW. U. L. REV. 749, 749 (2007). “Institutional Review Boards (‘IRBs’) are polarizing institutions. 
IRB supporters view them as the best thing since sliced bread. Detractors believe IRBs impose costs 
and have no benefits. Supporters point to the good faith and hard work of those who volunteer to 
serve on an IRB. Detractors suggest that IRBs emphasize bureaucratic busy-work. Supporters ask 
for more money and more staff so they can do an even more thorough job reviewing research 
protocols. Detractors point out that the IRB framework of research oversight would never be 
approved by an IRB. Supporters counter that notorious examples of abuse show that IRBs are 
necessary. Detractors respond with anecdotes of IRB stupidity and incompetence. Supporters argue 
that conducting research is a privilege, not a right. Detractors complain about censorship, 
restrictions on academic freedom, and the chilling of constitutionally protected free speech. Both 
sides then return to their respective camps, secure in the knowledge that they are right and those on 
the other side are self-righteous zealots.” Id. 
56. Jill Wechsler, FDA Hit for Poor Clinical Trial Oversight, SPECTROSCOPY (Nov. 1, 2007),
http://www.spectroscopyonline.com/spectroscopy/article/articleDetail.jsp?id=468088. 
10
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because it “lacks an efficient information system for tracking clinical 
research activity, site inspections, and resulting corrective actions.”57 
The FDA, in fact, oversees less than 1% of all clinical trials.58 As a 
consequence, patients may suffer serious delay in remedying issues that 
may arise during a clinical trial.59 The FDA inspects less than 300 IRBs 
each year, “partly because the agency has no complete IRB database and 
thus cannot identify all review boards evaluating clinical trials for 
regulated products.”60 
4. Medical Malpractice
Given the FDA’s limited oversight of IRBs, patients have turned to 
tort law and actions premised on lack of informed consent. “Medical 
malpractice occurs when a health care provider renders treatment that 
deviates from the accepted standard of practice in the medical 
community.”61 In other words, the care the doctor provided did not meet 
the level of care that should have been provided. Medical malpractice 
claims may be based either on deficient care in providing medical 
procedures or on failure to obtain informed consent prior to the 
procedure. The standard of care differs by jurisdiction and custom.62 It 
may be acceptable for a doctor to use a certain treatment in one locale 
but not in another.63 
Although the FDA cannot, and should not, micromanage all of the 
doctors in the United States to ensure compliance with established rules 
and regulations, these gaps in the oversight of medical care and research 
are more troubling when viewed in light of patient vulnerability to 
human experimentation. Understanding the FDA’s inability to oversee 
clinical trials and experimental treatments provides background for this 
57. Id.
58. Id.
59. Gardiner Harris, Report Assails F.D.A. Oversight of Clinical Trials, N.Y. TIMES (Sept.
28, 2007), http://www.nytimes.com/2007/09/28/health/policy/28fda.html?_r=3&. 
60. See Wechsler, supra note 56.
61. Robert P. Valletti, The Difficulty of Medical Malpractice: Deviation from Standard of
Care, GINARTE (Oct. 13, 2012), http://www.ginarte.com/2012/10/difficulty-medical-malpractice-
deviation-standard-care/. 
62. Id. “A major obstacle in medical malpractice claims, however, is proving there was an
actual deviation from a standard of care because the medical community is replete with doctors who 
render their own ‘opinion’ as to what the requisite level of care should have been. In laymen terms, 
doctors give their opinions as to what procedures or treatment should have been done based on a 
given set of facts surrounding a person’s symptoms, and since there is no ‘bright line’ rule about 
what types of procedures or treatments should be given (hence why it is called a doctor’s ‘opinion’), 
proving a deviation from the standard is difficult.” Id. 
63. Id.
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Comment’s argument that mere informed consent is not a sufficient 
safeguard for vulnerable patients. 
III. THE PROBLEM WITH INFORMED CONSENT
Medicine naturally seeks to balance a procedure’s benefits against 
its risks. Physicians and patients must constantly evaluate whether the 
risks of a given treatment are worth its benefits. Requiring a patient’s 
informed consent prior to a medical procedure attempts to protect both 
parties from making the wrong decision; but informed consent is often 
inadequate, given patients’ limited knowledge of medicine and their 
level of desperation.64 The law of informed consent was not developed 
to regulate use of experimental or innovative medicines or medical 
procedures, but it has been pressed into service in these areas. 
Accordingly, it provides an incomplete and often ineffectual solution. 
A. Should Informed Consent Bar Recovery? 
The doctrine of informed consent is premised upon the fundamental 
right of every person to determine what is done to his or her body in the 
course of medical treatment.65 The patient must be provided with enough 
information to make an informed decision regarding whether to accept 
or decline treatment.66 The elements of informed consent67 include 
64. See King & Moulton, infra note 70, at 430.
65. Russell G. Thornton, Informed Consent, BAYLOR UNIV. MED. CTR. (Apr. 2000),
available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1312305/. 
66. Id.
67. 45 C.F.R. § 46 (2005) currently reads as follows:
§46.116 General requirements for informed consent.
Except as provided elsewhere in this policy, no investigator may involve a human being 
as a subject in research covered by this policy unless the investigator has obtained the 
legally effective informed consent of the subject or the subject’s legally authorized 
representative. An investigator shall seek such consent only under circumstances that 
provide the prospective subject or the representative sufficient opportunity to consider 
whether or not to participate and that minimize the possibility of coercion or undue 
influence. The information that is given to the subject or the representative shall be in 
language understandable to the subject or the representative. No informed consent, 
whether oral or written, may include any exculpatory language through which the subject 
or the representative is made to waive or appear to waive any of the subject’s legal 
rights, or releases or appears to release the investigator, the sponsor, the institution or its 
agents from liability for negligence. 
(a) Basic elements of informed consent. Except as provided in paragraph (c) or (d) of 
this section, in seeking informed consent the following information shall be provided to 
each subject: 
(1) A statement that the study involves research, an explanation of the purposes of the 
research and the expected duration of the subject’s participation, a description of the 
12
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competence, disclosure, understanding, voluntariness, and 
authorization.68 A physician must explain the risks and benefits, as well 
as the purpose and duration of treatment, as part of the consent process.69 
Physicians obtain informed consent70 prior to any procedure to safeguard 
against legal liability.71 
There are two types of informed consent prevalent in America 
today.72 Approximately half of the states utilize a physician-based 
standard where physicians are expected to inform the patient about the 
procedures to be followed, and identification of any procedures which are experimental; 
(2) A description of any reasonably foreseeable risks or discomforts to the subject; 
(3) A description of any benefits to the subject or to others which may reasonably be 
expected from the research; 
(4) A disclosure of appropriate alternative procedures or courses of treatment, if any, that 
might be advantageous to the subject; 
(5) A statement describing the extent, if any, to which confidentiality of records 
identifying the subject will be maintained; 
(6) For research involving more than minimal risk, an explanation as to whether any 
compensation and an explanation as to whether any medical treatments are available if 
injury occurs and, if so, what they consist of, or where further information may be 
obtained; 
(7) An explanation of whom to contact for answers to pertinent questions about the 
research and research subjects’ rights, and whom to contact in the event of a research-
related injury to the subject; and 
(8) A statement that participation is voluntary, refusal to participate will involve no 
penalty or loss of benefits to which the subject is otherwise entitled, and the subject may 
discontinue participation at any time without penalty or loss of benefits to which the 
subject is otherwise entitled. 
68. See Kettle, supra note 5, at 60.
69. Id.
70. Jaime S. King & Benjamin W. Moulton, Rethinking Informed Consent: The Case for
Shared Medical Decision-Making, 32 AM. J.L. & MED. 429, 430 (2006), available at 
http://librarysource.uchastings.edu/repository/King/32AmJLMed429.pdf. The American Medical 
Association explains that sufficient information sharing by the physician, including all probable 
risks and benefits, is paramount in the process of obtaining adequate patient consent. W. Eugene 
Basanta, Communicating with Dying Patients, Proceedings of the 18th World Congress on Medical 
Law 1 (2010), available at http://www.law.siu.edu/_common/documents/
publications/basanta/communicating-patients.pdf. The American Medical Association goes on to 
explain, “The patient’s right of self-decision can be effectively exercised only if the patient 
possesses enough information to enable an informed choice. The patient should make his or her own 
determination about treatment. The physician’s obligation is to present the medical facts accurately 
to the patient or to the individual responsible for the patient’s care and to make recommendations 
for management in accordance with good medical practice. The physician has an ethical obligation 
to help the patient make choices from among the therapeutic alternatives consistent with good 
medical practice. Informed consent is a basic policy in both ethics and law that physicians must 
honor.” Id. 
71. Patient Consent, LAW, SCI. & PUB. HEALTH PROGRAM SITE, http://biotech.law.lsu.edu/
Books/aspen/Aspen-Patient.html (last visited Jan. 11, 2014). 
72. King & Moulton, supra note 70, at 430.
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risks that a “reasonably prudent practitioner” would be aware of.73 The 
other 23 states and the District of Columbia rely on a patient-based 
standard where physicians are expected to inform patients about the risks 
a “reasonable patient” would find valuable to the decision-making 
process.74 Patients may bring a negligence action against a physician by 
alleging that they did not receive adequate information before 
consenting to the procedure.75 A finding of informed consent, however, 
should not bar recovery when particular situations render the patient’s 
consent inadequate.76 
In addition to possible shortcomings in information provided by the 
physician, other fundamental problems with informed consent must be 
considered. For instance, patients tend to strongly believe that their 
physician would not recommend anything unnecessary or ineffective.77 
Patients may also struggle with information overload regarding the 
treatment and non-treatment options provided by their physician.78 Most 
patients are not familiar with medical terms and are unable to sift 
through complex and technical scientific information to understand what 
is important to their specific needs.79 
Moreover, special consideration must be given to obtaining 
informed consent from what the DHHS has termed “vulnerable 
73. Id.; Richard Weinmeyer, Lack of Standardized Informed Consent Practices and Medical
Malpractice, 16 AM. MED. ASSOC. J. ETHICS 120, 121 (2014). 
74. King & Moulton, supra note 70, at 430.
75. “The theory of negligence holds that the defendant is liable for a careless action or
omission when the defendant had an obligation toward the plaintiff and careless action or omission 
causes an injury. The standard of reasonable care is the level of care that a common person would 
view as proper conduct. On the other hand, the profession is the group that sets the standards for 
determining the level of due care in professional negligence or malpractice. Medical malpractice 
occurs when a physician violates the standard of due care, including an omission to properly 
disclose information about a specific procedure. In case of physicians’ negligence in informed 
consent, an action would have to show that a physician violated a duty of ‘due care to inform a 
patient, that this breach resulted in a financially measurable injury, and that a reasonable person 
would not have consented.’” Kettle, supra note 5, at 57-58. “Listing ‘informed consent’ as an 
allegation of negligence, within a medical malpractice suit, often does not give rise to a plaintiff 
being awarded damages as the lack of ‘informed consent’ alone is not a basis for neglect except 
when the plaintiff can prove the decision to proceed, or not proceed, with a procedure would have 
been made differently, and solely, upon the accurate facts of an informed consent, had it been given 
prior to surgery.” Christine Cadena, Medical Malpractice and the Informed Consent Doctrine (Feb. 
1, 2007), available at http://tinytuna.com/medical-malpractice-and-the-informed-consent-doctrine/. 
76. See Kettle, supra note 5, at 69.
77. Patient Consent, supra note 71.
78. Kettle, supra note 5. Contributing to this problem is patients’ reliance on selective
perception, making it difficult to figure out when words have a “special meaning for them, when 
preconceptions distort their processing of the information, and when other biases intrude.” Id. at 71. 
79. Id. at 68.
14
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subjects.”80 Groups such as children, the undereducated, the mentally 
handicapped, the terminally ill, and pregnant women are considered 
vulnerable populations.81 The common thread among these groups is that 
they may be more prone to coercion or undue influence while 
participating in experimental treatment.82 The terminally ill, for example, 
are of particular interest to this Comment. The patients in the brain 
bacteria case, discussed in the following section, are considered a special 
group because all three patients were terminally ill.83 Extra attention 
must be given to the terminally ill because they may be willing to try 
anything to improve their conditions and save their lives.84 
80. DEPT. OF HEALTH & HUMAN SERV., INSTITUTIONAL REVIEW BOARD GUIDEBOOK, ch. 6,
available at http://www.hhs.gov/ohrp/archive/irb/irb_chapter6.htm (last updated 1993). 
81. Id. Alarmingly, these special groups frequently suffer from institutional failures because
their unique needs are not adequately addressed prior to obtaining their informed consent. “In a 
cross-sectional survey of IRBs in U.S. institutions, investigators showed that IRBs rarely or never 
required procedures to determine capacity and also varied in their use of other safeguards, such as 
independent monitors, research proxies, and advance research directives.” Henry Silverman, 
Protecting Vulnerable Research Subjects in Critical Care Trials: Enhancing the Informed Consent 
Process and Recommendations for Safeguards, ANNALS OF INTENSIVE CARE, 2011, at 1, available 
at http://www.annalsofintensivecare.com/content/pdf/2110-5820-1-8.pdf. Although, the FDA has 
made exceptions for the terminally ill: it allows for “compassionate use” of a drug for those who are 
extremely desperate. “Expanded access,” sometimes called “compassionate use,” is the use of an 
investigational drug outside of a clinical trial to treat a patient with a serious or immediately life-
threatening disease or condition who has no comparable or satisfactory alternative treatment 
options. Expanded Access: Information for Patients, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Ap
provalApplications/InvestigationalNewDrugINDApplication/ucm351748.htm (last updated Oct. 4, 
2013). “FDA regulations allow access to investigational drugs for treatment purposes on a case-by-
case basis for an individual patient, or for intermediate-size groups of patients with similar treatment 
needs who otherwise do not qualify to participate in a clinical trial. They also permit expanded 
access for large groups of patients who do not have other treatment options available, once more is 
known about the safety and potential effectiveness of a drug from ongoing or completed clinical 
trials.” Compassionate Use Programs, ALS ASSOC., http://www.alsa.org/als-care/resources/
publications-videos/factsheets/compassionate-use.html (last visited Feb. 24, 2015). “Just as in 
clinical trials, these investigational drugs have not yet been approved by the FDA as safe and 
effective. They may be effective in the treatment of a condition, or they may not. They also may 
have unexpected serious side effects.” Id. 
82. Univ. of South Fla. IRB Training, Identifying and Protecting Vulnerable Populations,
available at TAMPA GEN. HOSP., https://www.tgh.org/PDFs/
IdentifyingandProtectingVulnerablePopulations.pdf (last visited Nov. 16, 2014). 
83. Marjie Lundstrom & Sam Stanton, Evaluation of UC Davis Medical Center’s Handling
of Neurosurgeons is Scathing, SACRAMENTO BEE, http://www.sacbee.com/2012/
12/23/5072625/evaluation-of-uc-davis-medical.html (updated Oct. 8, 2014, 10:39 AM). 
84. Natalie L. Regoli, Insurance Roulette: The Experimental Treatment Exclusion &
Desperate Patients, 22 QUINNIPIAC L. REV. 697, 697 (2004). This article describes an archetypal 
situation that closely mirrors the brain bacteria case. “During the last decade, the archetypal 
experimental treatment lawsuit has been one in which a gravely-ill patient petitions the court for an 
order directing his or her insurance company to authorize certain procedures. Such a case begins 
after standard medical treatment has failed, and the patient’s treating physician recommends newer 
15
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In summary, obtaining informed consent prior to an experimental 
procedure is not a sufficient safeguard for vulnerable patients. The law 
must intervene to protect patients who consent, as a last resort, to 
experimental treatments that may be ineffective or even unsafe.85 This 
gap between inadequate informed consent by desperate patients and the 
need for medical innovation can be filled by codification of the 
reasonable innovation rule. 
B. Autonomy Of Physician Decision Making 
As demonstrated by the previous sections of this Comment, 
regulation of medicine is necessary to protect patents. However, 
physician autonomy is a major concern when it comes to regulation of 
innovation and the medical profession. Advocates for greater physician 
autonomy maintain that greater autonomy and fewer regulations promote 
medical innovation.86 Each patient presents a unique situation where 
physicians may need to implement new or different techniques to best 
treat the patient.87 Excessive regulation and strict guidelines curb 
creativity crucial to physicians and the medical profession as a whole.88 
In order to attract talented professionals, the field of medicine must trust 
physicians to self-regulate.89 Loss of autonomy is one of the most 
common complaints of physicians who report feeling disenchanted with 
their careers.90 
Nonetheless, there must be a balance between regulation and 
autonomy to protect patients from consenting to procedures that are not 
yet approved for widespread use. The FDA continuously struggles with 
treatments out of the belief that they are the best opportunity to sustain the patient’s health and life. 
In the patient’s desperate efforts to procure whatever treatments may improve her condition, the 
patient decides to assume the risk of these new treatments.” Id. 
85. Id. at 699.
86. Richard L. Reece, Government Regulation and Physician Autonomy, MEDINNOVATION &
HEALTH REFORM (Apr. 1, 2010), http://medinnovationblog.blogspot.com/2010/04/thoughts-on-
government-regulation-and.html. 
87. Id.
88. Id. The article argues, “Physicians struggle to improve quality, safety and efficiency in an
imperfect world of clinical practice that is overwhelmed with information, laced with ambiguity and 
plagued by deepening physician shortages. From an organizational perspective, they require 
sufficient numbers of colleagues, a supportive infrastructure, adequate reimbursement and freedom 
from administrative and regulatory intrusion. High quality care depends on the autonomous exercise 
of clinical judgment by competent and empathic physicians who are accountable to their patients 
and society. No amount of regulation or incentives can substitute.” Id. 
89. David Orentlicher, The Influence of a Professional Organization on Physician Behavior,
57 ALB. L. REV. 583, 585 (1994). 
90. Id.
16
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this balance in deciding when and how to regulate.91 As the fecal 
transplant portion of this paper will demonstrate, the FDA is hesitant to 
regulate when beneficial innovation is occurring. In that case, an 
innovative procedure—a fecal transplant—is resulting in an unusually 
high success rate: over 90% of patients who undergo the procedure 
experience complete elimination of symptoms.92 Thus, the fine line 
between experimentation and innovation is once again tested. 
IV. UNDERSTANDING THE SOLUTION TO INADEQUATE INFORMED
CONSENT THROUGH CASE STUDIES 
Now that this Comment has explored the problems with informed 
consent, it will shift focus to the solution for inadequate informed 
consent: codifying the reasonable innovation rule. This will be achieved 
by exploring instances where doctors used novel microbial experimental 
treatments that were not FDA-approved after obtaining informed 
consent. 
First, subsection A will present a preliminary explanation of the 
microbiome. Next, subsections B and C will discuss two very different 
studies involving the use of microbial transplants. In the first study, 
surgeons introduced live bacteria to the brains of three patients in hopes 
of curing brain tumors, but this had deadly consequences. In the second 
study, physicians introduced healthy fecal bacteria to patients’ colons to 
cure chronic diarrhea, and this treatment had a 90% success rate. 
Subsection D will compare the two studies to demonstrate why informed 
consent is an inadequate safeguard for vulnerable patients. Subsection E 
will introduce the reasonable innovation rule and explore its scope by 
comparing two cases. Subsection F will argue for codification of the 
reasonable innovation rule. Finally, subsection G will propose language 
for codification. 
A. Human Experimentation in the Context of the Microbiome 
The human body has over ten times more “bugs”—microbes that 
live in the guts, mouth, and skin—than human cells; the human body is 
“vastly more microbe than human.”93 The microbiome was first 
91. MICHAEL MANDEL, PROGRESSIVE POLICY INST., HOW THE FDA IMPEDES INNOVATION:
A CASE STUDY IN OVERREGULATION (2011), available at http://progressivefix.com/wp-
content/uploads/2011/06/06.2011-Mandel_How-the-FDA-Impedes-Innovation.pdf. 
92. McKenna, supra note 7.
93. Karen Weintraub, Microbiome: How Bugs May Be Crucial to Your Health, BBC,
http://www.bbc.com/future/story/20120412-the-beasts-inside-you (last visited Nov. 16, 2014). 
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discovered in 1683 when Antoine Van Leeuwenhoek scraped “gritty 
matter” off of his teeth and analyzed it under a microscope.94 This 
experiment and its findings made him the first person to conceptualize 
bacteria in the mouth.95 Over the centuries, the microbiomes that play 
such a crucial role in human health have remained mostly a mystery.96 
This is largely because it was nearly impossible to isolate and cultivate 
more than 95% of our microorganisms in simulated laboratory 
conditions.97 However, recent advances in DNA sequencing have made 
it possible to study microbiomes without cultivating them in a 
laboratory.98 Now that science is beginning to understand the effect that 
these microscopic bugs have on our health, coupled with the fact that a 
viable means of studying microbiomes now exists, the need for 
volunteer donors has skyrocketed.99 As science enters this new realm of 
understanding how microscopic bugs interact with the human body and 
how to use this knowledge to treat or cure existing disease, society must 
decipher what constitutes innovative treatment and what constitutes 
human experimentation. 
Two case studies involving microbial experimentation illustrate the 
conflict between the need for patient protection and the need for 
innovative medicine. The first highlights the inadequacies of informed 
consent, while the second demonstrates regulators’ hesitation to 
intervene where innovation is occurring. 
B. The Bacterial Transplant Case 
In 2010 and 2011, three seriously ill patients at UC Davis Medical 
Center consented to have their skulls opened and live bacteria introduced 
to their brains.100 Two highly regarded neurosurgeons believed that 
introducing Enterobacter aerogenes101 to the patients’ brains would wipe 
94. Michael J. Cox, William O.C.M. Cookson & Miriam F. Moffat, Sequencing the Human
Microbiome in Health and Disease, 22 HUMAN MOLECULAR GENETICS R88, R88 (2013), available 
at http://hmg.oxfordjournals.org/content/22/R1/R88.full.pdf. 
95. Id.
96. Weintraub, supra note 93.
97. The Human Microbiome Project, BAYLOR COLL. OF MED., https://www.bcm.edu/
departments/molecular-virology-and-microbiology/research/the-human-microbiome-project (last 
visited Nov. 16, 2014). 
98. Id.
99. Faith Rohlke & Neil Stollman, Fecal Microbiota Transplantation in Relapsing
Clostridium Difficile Infection, 5 J. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 403, 403 
(2012). 
100.  See Lundstrom & Stanton, supra note 83. 
 101.  Enterobacter Aerogenes, BIOQUELL, 
http://www.bioquell.com/technology/microbiology/enterobacter-aerogenes/ (last visited Nov. 22, 
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out the patients’ deadly glioblastomas after the bacteria colonized.102 All 
three patients, however, died after their transplants.103 Two died from 
entering a septic shock just 14 days after surgery, and the last patient 
lived a year but had to endure several more painful procedures due to 
surgical complications.104 
The neurosurgeons were able to perform these procedures because 
they obtained informed consent from all three patients.105 The consent 
forms were a mere 300 words that took up just one page, warning the 
patients of the procedure’s dangers.106 “‘There is no proof that such 
treatment (for brain cancer) might be beneficial,’ the form read, ‘nor are 
there animal data to support it.’”107 The form went on to detail the 
consequences and risks of introducing the bacteria to the patients’ 
brains, including “paralysis, inability to speak or understand speech, 
inability to swallow, vegetative state, coma or death.”108 The surgeon 
later claimed that, when the patients gave their express informed 
consent, they were all “of sound mind,” and “their disease did not affect 
their judgment” or decision-making ability.109 
The surgeons purchased the bacteria from a Virginia lab after the 
FDA ordered rigorous animal testing before “contemplating the 
bacteria’s use in live patients.”110 Despite this, in a desperate attempt to 
prolong the patients’ lives, the neurosurgeons circumvented the FDA 
and IRB regulations and approval and infected the patients.111 It was 
reported that, after interviewing 27 doctors, nurses, and hospital staff, no 
2013). Enterobacter aerogenes is commonly found in the human gastrointestinal tract. Enterobacter 
Aerogenes, CUVERRO, http://cuverro.com/tested-proven-trusted/scientific-proof/epa-tests/
enterobacter-aerogenes (last visited Dec. 27, 2014). 
 102.  Glioblastoma, AM. BRAIN TUMOR ASS’N, http://www.abta.org/understanding-brain-
tumors/types-of-tumors/glioblastoma.html (last visited Nov. 22, 2013). “Glioblastomas are tumors 
that arise from astrocytes—the star-shaped cells that make up the ‘glue-like,’ or supportive tissue of 
the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce 
quickly and they are supported by a large network of blood vessels. . . . Glioblastoma can be 
difficult to treat because the tumors contain so many different types of cells. Some cells may 
respond well to certain therapies, while others may not be affected at all. This is why the treatment 
plan for glioblastoma may combine several approaches.” Id. 
103.  Lundstrom, supra note 8. 
 104.  Marjie Lundstrom, Impact, Ethics of Surgery Slammed, SACRAMENTO BEE, 
http://www.sacbee.com/2013/02/11/5180237/impact-ethics-of-surgery-slammed.html (updated Oct. 
6, 2014, 2:38 PM). 
105.  Lundstrom, supra note 8. 
106.  Lundstrom, supra note 104. 
107.  Id. 
108.  Id. 
109.  Id. 
110.  Id. 
111.  Id. 
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one was willing or able to report unsafe care practices they witnessed.112 
The hospital personnel trusted the neurosurgeons so much as to not 
question the highly unusual procedure.113 Both neurosurgeons have since 
resigned, and the families of the deceased patient-victims have settled 
their claims against the university.114 Now, complex questions remain 
“about the nature of consent, what constitutes research[,] and how to 
safeguard vulnerable patients.”115 
C. The Fecal Transplant Case: An Increasingly Popular Cure for an 
Old Problem116 
Feces can save lives. Over 14,000 lives a year, to be exact.117 Once 
one overcomes the initial “ick factor,” the prospect of safe, regulated, 
extremely effective fecal microbiota transplants (“FMT’s”) can bring 
hope to thousands of Americans who suffer from Clostridium difficile 
(“C. diff”) infections. Earlier this year, the FDA announced that it would 
require IND applications for fecal microbiota transplantations to treat C. 
diff infections for purposes of patient safety.118 Shortly after the 
announcement, primarily due to negative pushback from advocates of 
FMT, the FDA backed away from regulating the procedure and decided 
that it would no longer require a physician to submit an IND application 
prior to performing a fecal transplant.119 Instead, the FDA’s draft 
guidance merely requires physicians to obtain informed consent from 
patients before they undergo the transplant.120 An examination of FMTs 
demonstrates the FDA’s reluctance to step in when physicians push for 
greater autonomy with respect to successful, novel treatments. 
1. The Fecal Transplant Case
One-thousand seven-hundred years ago, a Chinese doctor first 
112.  Lundstrom & Stanton, supra note 83. 
113.  Id. 
114.  Lundstrom, supra note 8. 
115.  Id. 
116.  C. diff was discovered in 1935, yet scientists did not recognize it as the major cause of 
antibiotic-associated diarrhea until 1978. Clostridium Difficile: An Intestinal Infection on the Rise, 
HARVARD HEALTH PUBL’NS (June 1, 2010), 
http://www.health.harvard.edu/newsletters/Harvard_Mens_Health_Watch/2010/June/clostridium-
difficile-an-intestinal-infection-on-the-rise. 
 117.  Clostridium Difficile Infection, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html (last updated Mar. 1, 2013). 
118.  Investigational New Drug (IND) Application, infra note 168. 
119.  Gaffney, infra note 175. 
120.  Id. 
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prescribed “drinking liquefied feces as a treatment for severe diarrhea 
and food poisoning.”121 Subsequently, the use of fecal transplants was 
limited to veterinary medicine where the practice has been performed for 
over 100 years.122 The first human fecal transplant was mentioned in a 
1958 case series123 where four patients were treated for their 
pseudomembranous enterocolitis.124 It noted that three of the four 
patients were in critical condition when the fecal enemas were 
administered.125 Surprisingly, all four patients’ symptoms resolved 
within hours of receiving the fecal transplant.126 The first case 
confirming treatment of C. diff by means of a fecal microbiota transplant 
was documented in 1983.127 The procedure, however, did not gain wide 
acceptance in the medical community due to the lack of controlled 
clinical trials.128 
Thus, the notion of curing gastrointestinal problems with an FMT 
was nearly unheard of in 2011 when 79-year-old Marion Browning, a 
retired nurse, began suffering from painful, chronic diarrhea.129 This 
ailment, which lasted nearly a year, occurred after she was prescribed 
antibiotics to treat her diverticulitis.130 Unfortunately, the antibiotics also 
 121.  Diane Suchetka, Ohio Hospitals Now Performing Fecal Transplants for Patients with 
Stubborn Cases of C. diff, CLEVELAND PLAIN DEALER (Jul. 8, 2013, 6:20 AM), 
http://www.cleveland.com/metro/index.ssf/2013/07/three_ohio_hospitals_now_perfo.html. 
 122.  Lawrence J. Brandt, Fecal Transplantation for the Treatment of Clostridium Difficile 
Infection, 8 J. GASTROINTESTINAL & HEPATOLOGY 191, 191 (2012), available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365524/. 
 123.  Ryan Jaslow, Fecal Transplants Beat Antibiotics for Curing Diarrhea Caused by C. 
Difficile, CBS NEWS (Jan. 17, 2013, 11:10 AM), http://www.cbsnews.com/8301-204_162-
57564470/fecal-transplants-beat-antibiotics-for-curing-diarrhea-caused-by-c-difficile/. 
 124.  Johan S. Bakken et al., Treating Clostridium Difficile Infection with Fecal Microbiota 
Transplantation, 9 J. CLIN. GASTROENTEROLOGY & HEPATOLOGY 1044, 1044 (2011), available at 
http://www.cghjournal.org/article/S1542-3565%2811%2900891-3/abstract. “Pseudomembranous 
colitis is inflammation of the colon that occurs in some people who have taken antibiotics. 
Pseudomembranous colitis is sometimes called antibiotic-associated colitis or C. difficile colitis. 
The inflammation in pseudomembranous colitis is almost always associated with an overgrowth of 
the bacterium Clostridium difficile.” Pseudomembranous Colitis, MAYO CLINIC (Dec. 5, 2012), 
http://www.mayoclinic.com/health/pseudomembranous-colitis/DS00797. 
125.  Bakken et al., supra note 124, at 1045. 
126.  Id. 
127.  Id. 
128.  B. Guo et al., Systematic Review: Faecal Transplantation for the Treatment of 
Clostridium Difficile-Associated Disease, 35 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 865, 
873 (2012). 
129.  McKenna, supra note 7. 
 130.  Id. Diverticulitis is a condition where “small pouches protrude from the walls of the 
colon. . . . Diverticulosis itself is really not a problem, as the pouches themselves are harmless and 
rarely cause symptoms. However, the situation becomes more serious if the pouches become 
infected from, for example, stool getting trapped in the pouch.” Diverticulosis and Diverticulitis, 
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killed the friendly bacteria in Browning’s intestines, allowing a toxin-
producing bacteria, C. diff,131 to colonize and start “eating away at the 
entire lining of her gut.”132 Browning spent months visiting different 
doctors, searching for a cure.133 Each visit resulted in a stronger 
antibiotic to attempt to cure the C. diff, and while her condition would 
improve at first, the antibiotics were ultimately unable to eliminate all of 
the infection.134 After four rounds of powerful antibiotics, Browning’s 
gastroenterologist informed her that he tried everything he could and 
referred her to Colleen Kelly, a clinical researcher at the medical school 
at Brown University.135 Finally, a cure for Browning’s painful C. diff 
was in sight.136 What Kelly proposed sounded both “logical and 
strangely unmedical”:137 she wanted Browning to receive a fecal 
transplant.138 
Healthy intestinal bacteria usually maintain a balance with 
pathogenic bacteria,139 but in fragile individuals such as children, the 
elderly, or immunosuppressed people, the overuse of antibiotics can 
cause overgrowth of C. diff.140 Once there is an overgrowth of C. diff., 
patients experience days of severe diarrhea, which is extremely 
dehydrating and can result in death if the condition persists.141 In 
Browning’s case, the powerful antibiotics prescribed to her upset the 
healthy balance of intestinal bacteria, resulting in a severe case of C. 
INT’L. FOUND. FOR FUNCTIONAL GASTROINTESTINAL DISORDERS, http://www.iffgd.org/site/gi-
disorders/other/diverticulosis (last modified Sept. 16, 2014, 10:40 AM) (adapted from IFFGD 
Publication #153 by Cheri Smith, Medical Writer). 
 131.  Clostridium Difficile Infection, supra note 117. C. diff causes inflammation of the colon 
due to prolonged use of antibiotics. “The main clinical symptoms of C. difficile infection (CDI) are 
watery diarrhea, fever, nausea, abdominal pain/tenderness, and loss of appetite. More serious 
conditions can also result such as pseudomembranous colitis (inflammation of the colon), 
perforations of the colon, and sepsis. It is possible to carry C. diff bacteria in your body but not 
show any symptoms; this is called colonization. After treatment, repeat testing is not recommended 
if the patient’s symptoms have resolved, since many patients remain colonized with the bacteria.” 
Clostridium Difficile (C. Difficile) Infections, VA. DEPT. OF HEALTH, http://
www.vdh.virginia.gov/epidemiology/surveillance/hai/cdiff.htm (last updated Apr. 3, 2014). 
132.  McKenna, supra note 7. 
133.  Id. 
134.  Id. 
135.  Id. 
136.  Id. 
137.  Id. 
138.  Id. There are many names for fecal transplants. They are “variously called fecal 
transplant, fecal bacteriotherapy or fecal flora reconstitution.” Id. 
139.  Id. 
140.  Clostridium Difficile Infection, supra note 117. 
141.  Id. 
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diff.142 Kelly reasoned that, if she took a diluted stool sample from a 
healthy donor, the good bacteria could recolonize in Browning’s 
intestine and wipe out the infection.143 Browning, desperate to try 
anything after enduring months of gut-wrenching diarrhea, chose her son 
as her donor.144 Kelly diluted the sample and used colonoscopy 
instruments to introduce the sample into Browning’s large intestine.145 
The results were astounding: Browning’s diarrhea was completely 
eliminated within two days and never recurred.146 
2. Recent Developments in Fecal Transplants
Browning’s success story did not go completely unrecognized: “in 
medical journals, about a dozen clinicians in the U.S., Europe, and 
Australia have described performing fecal transplants on about 300 C. 
difficile patients so far.”147 Although fecal transplants are not unheard 
of, their success rate is.148 More than 90% of patients recover completely 
after receiving a fecal transplant.149 This statistic is encouraging due to 
an increased occurrence of C. diff since a new epidemic strain emerged 
in 2004.150 As a result of the antibiotic resistant C. diff strain, cases of 
those infected have “doubled from about 134,000 patients in 2000 to 
291,000 patients in 2005.”151 Another study showed that mortality rates 
have increased “fourfold, from 5.7 deaths per million in the general 
population in 1999 to 23.7 deaths per million in 2004.”152 Furthermore, 
not only does C. diff pose an alarming threat to human life, but it also 
142.  McKenna, supra note 7. 
143.  Id. 
144.  Id. 
145.  Id. 
146.  Id. 
147.  Id. 
148.  Id. 
149.  Id. “‘There is no drug, for anything, that gets to 95 percent,’ Kelly says. Plus, ‘it is cheap 
and it is safe,’ says Lawrence Brandt, a professor of medicine and surgery at the Albert Einstein 
College of Medicine, who has been performing the procedure since 1999.” Id. 
 150.  Information About the Current Strain of Clostridium Difficile, CTRS. FOR DISEASE 
CONTROL & PREVENTION, http://www.cdc.gov/HAI/organisms/cdiff/Cdiff-current-strain.html (last 
updated 2010). “Over the past several years nationwide, states have reported increased rates of C. 
difficile infection, noting more severe disease and an associated increase in mortality. C. diff 
infection remains a disease mostly associated with healthcare (at least 80%). Patients most at risk 
remain the elderly, especially those using antibiotics. Although the elderly are still most affected, 
more disease has been reported in traditionally ‘low risk’ persons such as healthy person in the 
community, and peripartum women.” Id. 
151.  McKenna, supra note 7. 
152.  Id. 
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presents a startling economic cost.153 Studies estimate the daily cost of 
C. diff treatment to be between $17.6 million and $51.5 million,154 
bringing “the national cost of C. diff treatment between $1 billion and 
$3.2 billion, conservatively.”155 These figures illustrate the need for an 
effective, inexpensive treatment, which fecal transplants can fulfill. 
Cases like Browning’s began to increase interest in FMT research. 
In January 2013, the New England Journal of Medicine published the 
results of a study that advocated for the use of fecal microbiota 
transplants.156 The “52-patient study . . . compared the efficacy of 
treatment with vancomycin, an antibiotic, and FMT in patients who 
suffered from C. diff and had at least one relapse after antibiotics.”157 
The study found that subjects who were suffering from C. diff had 
decreased microbial diversity and introduction of healthy donor feces 
increased the diversity, eliminating the C. diff. 158 This study also 
emphasized that the best method for administering a fecal transplant 
remains unknown.159 It explained, “Up until 1989, retention enemas had 
been the most common technique for FMT. However, alternative 
methods subsequently included fecal infusion via duodenal tube in 1991, 
rectal tube in 1994, and colonoscopy in 1998.”160 
In October 2013, a new method of performing a fecal transplant 
was introduced: the pill form.161 A Canadian disease specialist, Dr. 
Thomas Louie, performed a study on 31 patients suffering from C. 
diff.162 Each subject took 24-34 capsules of fresh, healthy fecal bacteria, 
coated in gelatin to maintain integrity in the stomach before reaching the 
 153.  Syed Sayeed et al., Hospital-Acquired C. Difficile Infections, CONSUMERS UNION (Nov. 
2008), http://consumersunion.org/pub/Final%20Cdiff%20Policy%20Brief%2011-11-08.pdf. 
 154.  Id. “These figures do not take into account health care costs outside of the hospital or 
nursing home, lost productivity, pain and suffering of patients or the time that medical professionals 
must spend treating them.” Id. 
155.  Id. 
 156.  Alexander J. Varond, Fecal Microbiota Transplantation: FDA Announces Limited 
Enforcement Discretion, FDA L. BLOG (Jul. 23, 2013), http://www.fdalawblog.net/
fda_law_blog_hyman_phelps/2013/07/fecal-microbiota-transplantation-fda-announces-limited-
enforcement-discretion.html. 
157.  Id. 
158.  Els van Nood et al., Duodenal Infusion of Donor Feces for Recurrent Clostridium 
Difficile, 368 NEW ENG. J. MED. 407, 414 (Jan. 31, 2013), available at http://www.nejm.org/
doi/full/10.1056/NEJMoa1205037#t=articleBackground. 
159.  Id. 
160.  Bakken et al., supra note 124. 
161.  Sarah Zhang, Feces-Filled Pill Stops Gut Infection, SCI. AM. (Oct. 7, 2013), 
http://www.scientificamerican.com/article.cfm?id=feces-filled-pill-stops-gut-infection. 
162.  Id. 
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intestines intact.163 The pills cured 30 of the 31 patients.164 Dr. Louie 
reported that lab-grown bacteria for the pills may be a future innovation, 
and he is currently experimenting with freezing donor fecal matter for 
later treatment.165 These studies not only provided a modern-day test of 
the efficacy of fecal transplants, they also caught the attention of the 
FDA.166 
3. The FDA’s Attempt at Regulating Fecal Microbiota
Transplants
In early May 2013, the FDA held a workshop to “provide a forum 
for the exchange of information, knowledge, and experience” regarding 
fecal transplants.167 After gathering information from the workshop, the 
FDA announced that it would require doctors who were performing fecal 
transplants to submit an  IND168 application prior to the procedure in 
non-emergency situations.169 This new regulation did not affect clinical 
trials because they were already subject to FDA approval.170 The FDA 
guidelines provide that, “[o]nce the IND is submitted, the sponsor must 
wait 30 calendar days before initiating any clinical trials. During this 
time, the FDA has an opportunity to review the IND for safety to assure 
that research subjects will not be subjected to unreasonable risk.”171 
However, the FDA explained that physicians could obtain approval via 
163.  Id. 
164.  Id. 
165.  Id. 
166.  Varond, supra note 156. 
167.  Public Workshop: Fecal Microbiota for Transplantation, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm34
1643.htm (last updated Mar. 10, 2014). 
 168.  Investigational New Drug (IND) Application, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approv
alapplications/investigationalnewdrugindapplication/default.htm (last updated Oct. 27, 2014). 
“Current Federal law requires that a drug be the subject of an approved marketing application before 
it is transported or distributed across state lines. Because a sponsor will probably want to ship the 
investigational drug to clinical investigators in many states, it must seek an exemption from that 
legal requirement. The IND is the means through which the sponsor technically obtains this 
exemption from the FDA. During a new drug’s early preclinical development, the sponsor’s primary 
goal is to determine if the product is reasonably safe for initial use in humans, and if the compound 
exhibits pharmacological activity that justifies commercial development. When a product is 
identified as a viable candidate for further development, the sponsor then focuses on collecting the 
data and information necessary to establish that the product will not expose humans to unreasonable 
risks when used in limited, early-stage clinical studies.” Id. 
 169.  Beth Mole, FDA Comes to Grips with Fecal Transplants, SCI. AM. (June 12, 2013), 
http://www.scientificamerican.com/article.cfm?id=fda-comes-to-grips-with-fecal-transplants. 
170.  Id. 
171.  Investigational New Drug (IND) Application, supra note 168. 
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phone or “other rapid means of communication” in an emergency.172 
The move to regulate fecal transplants to ensure proper safety and 
oversight met with strong criticism from physicians.173 Physicians 
argued that “the added burdens of adhering to clinical trials regulations 
would make the therapy more difficult, more expensive, more time-
consuming, and, ultimately, drive more patients to engage in do-it-
yourself fecal transplants.”174 This criticism caused the FDA to quietly 
amend its previously issued guidelines regarding fecal transplants. In 
July 2013, just one month after the FDA announced that it would require 
IND applications from physicians, the FDA removed this requirement 
altogether.175 “While maintaining its authority to require the submission 
of an IND in some cases, [the FDA] would resort to a policy of 
‘enforcement discretion’ under which it would allow most practitioners 
to continue to conduct FMT procedures without an approved IND.”176 
This “enforcement discretion” merely requires the physician to obtain 
informed consent prior to performing a fecal transplant.177 The FDA 
further instructed that the informed consent “should, at a minimum, 
include a statement that the FMT product is still investigational and 
involves assuming potential risks.”178 
There are dangers associated with any procedure, and fecal 
transplants are not exempt from this. Despite the apparent success of 
FMTs, the procedure is still highly experimental. The human 
gastrointestinal tract is filled with bacteria—good and bad—and can be 
riddled with “viruses, fungi, protozoa and parasites.”179 There is a 
possibility of transmitting “HIV, prion disease, e. coli 0157:H7, worms, 
shigella, and other dysentery-causing infectious agents.”180 Since fecal 
transplants did not undergo the rigors of clinical trials, the best method 
 172.  Kristina Fiore, Fecal Transplant: FDA Wants Regulation, MED PAGE TODAY (May 15, 
2013), http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/39169. 
 173.  Alexander Gaffney, FDA Fast Tracks Fecal Transplant Product Intended to Treat 
Clostridium Difficile Infections, REGULATORY FOCUS (June 25, 2013), http://www.raps.org/focus-
online/news/news-article-view/article/3681.aspx. 
174.  Id. 
 175.  Alexander Gaffney, Regulatory Approach for Fecal Transplant Product Finalized in 
Abrupt Guidance Document, REGULATORY FOCUS (July 17, 2013), http://www.raps.org/focus-
online/news/news-article-view/article/3795/regulatory-approach-for-fecal-transplant-product-
finalized-in-abrupt-guidance-d.aspx. 
176.  Id. 
177.  Id. 
178.  Id. 
179.  Val Jones, Fecal Transplants: Getting to the Bottom of the Matter, SCIENCE-BASED MED. 
(Nov. 27, 2008), http://www.sciencebasedmedicine.org/fecal-transplants-getting-to-the-bottom-of-
the-matter/. 
180.  Id. 
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for receiving a transplant (pill, colonoscopy, enema or nasoduodenal 
tube) and the best diluent (water or milk or other) are among the many 
questions that remain unanswered.181 Thus, scholarship has concluded 
that more research is required before FMTs “can be widely 
advocated.”182 
Furthermore, the loosening of restrictions regarding fecal 
transplants illustrates that the FDA does not want to regulate areas where 
new experiments are proving highly successful. Physicians continue to 
experiment with conducting fecal transplants on patients while merely 
obtaining informed consent.183 At least three Ohio hospitals routinely 
offer the procedure to their patients.184 The success rate of fecal 
transplants makes it tempting to view the new treatment as an exciting 
innovation; there is, however, a fine line between innovation and 
experimentation. The efficacy of fecal transplants came from “a long 
series of successful case studies in the course of treatment, not clinical 
trials.”185 Most fecal transplants were performed without IRB approval 
or FDA oversight.186 It can be argued that there is never innovation 
without experimentation, but this begs the question where should we 
draw the line.187 
D. Comparing the Cases 
These two cases—one involving fecal transplant and one involving 
bacterial transplants in the brain—are similar because the bacterial 
transplants in the brain were, and fecal transplants are, conducted 
without FDA or IRB oversight. Both procedures are experimental and 
require informed consent. Both procedures involve the novel concept of 
transplanting microbiomes in hopes that they would colonize and 
overcome the existing infection. The results, however, were strikingly 
different. One must wonder, “[I]f [the bacterial transplants in the brain] 
 181.  Judy Stone, The S**t Hits the Fan—FDA, INDs, and Fecal Microbiota Transplants, SCI. 
AM. (May 20, 2013), http://blogs.scientificamerican.com/molecules-to-medicine/2013/05/20/the-st-
hits-the-fan-fda-inds-and-fecal-microbiota-transplants/. 
 182.  Zain Kassam et al., Fecal Microbiota Transplantation for Clostridium Difficile Infection: 
Systematic Review and Meta-Analysis, 108 AM. J. GASTROENTEROLOGY 500, 508 (2013). 
183.  Mole, supra note 169. 
184.  Suchetka, supra note 121. 
185.  Nicholson Price, Experiment vs. Innovative Treatment in Bacterial Transplants, BILL OF 
HEALTH (Aug. 27, 2013), http://blogs.law.harvard.edu/billofhealth/2013/08/27/experiment-vs-
innovative-treatment-in-bacterial-transplants/. 
186.  Id. 
 187.  See generally Nancy M. P. King, The Line Between Clinical Innovation and Human 
Experimentation, 32 SETON HALL L. REV. 573 (2002). 
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had worked, would the reaction have been the same, or would the 
surgeons have been hailed as innovators and heroes?”188 
E. The Reasonable Innovation Rule 
Patients, however, would be safeguarded against unreasonable, 
inadequately researched treatments suggested by physicians if the 
reasonable innovation rule were codified. The doctors in the brain 
bacteria case would not have been permitted to perform the procedure 
under the reasonable innovation rule because adequate medical research 
was not conducted prior to the experiment. The reasonable innovation 
rule would set minimum standards higher than those required for 
informed consent. If this rule were codified, doctors would assume a 
larger role in providing reasonable treatment to their patients. 
1. The Common Law Rule
The reasonable innovation rule states that, if customary care is 
unlikely to provide an adequate treatment for a particular patient, a 
doctor may reasonably innovate to meet the unique needs of the 
patient.189 Everyday medicine requires physicians to exercise quick 
decision-making skills, and therapeutic innovation is permissible when 
customary care does not work for a patient.190 Each patient presents a 
different challenge, and reasonable innovation is necessary to meet the 
unique needs of each patient.191 
2. The Scope of the Rule
It is important to identify the proper scope of a rule that fills the gap 
between innovation and experimentation. The limits of the rule will be 
illustrated by contrasting two cases where doctors implemented a new 
technique with opposite results. The court in the Brook v. St. John’s 
Hickey Memorial Hospital case, discussed in the following section, laid 
out factors to determine what constitutes a reasonable innovation.192 The 
court found the physician in that case had compelling professional 
reasons for deviating from customary care by implementing an 
innovation.193 First, he consulted medical journals and other professional 
188.  Price, supra note 185. 
189.  Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 76 (Ind. 1978). 
190.  Id. 
191.  Id. 
192.  Id. 
193.  Id. 
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articles that warned against using customary care.194 Next, he 
successfully implemented the innovation on other similar patients.195 
Because of these two factors, the court concluded that his deviation from 
the standard of care was reasonable. 
a. Brook v. St. John’s Hickey Memorial Hospital
The first case illustrates how the reasonable innovation rule is 
applied in practice. In Brook vs. St. John’s Hickey Memorial Hospital, a 
specialist diagnosed a two-year-old with a possible urological 
disorder.196 The specialist ordered X-rays taken with a contrast 
medium197 to confirm the diagnosis.198 A radiologist injected the contrast 
medium into the child’s calves because he was not able to find a vein in 
which he could inject the medium.199 The contrast medium came in a 
package accompanied by the manufacturer’s instructions for injection.200 
The instructions specifically recommended that the medium be injected 
into the gluteal muscles (buttocks).201 The radiologist, however, was 
familiar with medical scholarship that warned against intramuscular 
injection into the buttocks of young children because of the potential for 
nerve and muscle damage.202 The doctor decided to inject the medium 
into the child’s legs because “they were the next largest muscle mass 
away from the trunk of the body.”203 
194.  Id. at 77. 
195.  Id. 
196.  Id. at 73. 
197.  “The contrast agent (also called contrast media, contrast material, X-ray dye, or 
gadolinium contrast) shows up white on X-ray, CT, and MR images. This makes . . . organs, blood 
vessels, and tissues more visible, which helps . . . interpret these imaging studies.” Contrast 
Injections for Imaging Studies, UNIV. OF WASH. MED., available at 
http://www.uwmedicine.org/services/radiology/Documents/Articles/Contrast_Injections_Imaging_S
tudies_2_10.pdf (last visited Feb. 16, 2015). 
198.  Brook, 380 N.E.2d at 73-74. 
199.  Id. at 74. 
200.  Id. 
201.  Id. 
202.  Id. The warning in the American Medical Association Journal specifically warned, 
“anyone concerned with infants and children must be aware that injection into the buttock may 
cause paralysis in the lower extremity. It is not often recognized that serious sciatic nerve injury can 
result from intragluteal administration of therapeutic and prophylactic agents. Injection injury of the 
sciatic nerve is more common than supposed and may be responsible for paralytic deformities 
which may be misdiagnosed as congenital club feet or the sequelae of poliomyelitis. The newborn 
infant, and especially the small premature infant, is more likely to suffer from this complication. 
Any age group is vulnerable, and injury may result from a solitary injection. By abandoning the 
intragluteal site and choosing another area for intramuscular injections, physicians may spare their 
patients unnecessary handicaps.” Id. at 75. 
203.  Id. at 74. 
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Four months after the injection, the child’s leg became stiff, and her 
heel began to lift off of the ground.204 This problem was due to the 
shortening of her Achilles tendon and may have been caused by the 
intramuscular injection.205 Fortunately, after two operations and 
extensive treatment, the child’s condition was “substantially 
corrected.”206 The child’s parents, however, sued the radiologist, along 
with the hospital and two other physicians, alleging that “[the 
radiologist] was negligent in choosing an injection site which had not 
been specifically recommended by the medical community and that this 
choice of an unusual injection site was a medical experiment.”207 The 
jury returned a verdict in favor of the radiologist,208 but the appellate 
court reversed.209 The Indiana State Supreme Court then affirmed the 
trial court’s judgment.210 In so doing, the Indiana Supreme Court 
reasoned that the radiologist had several compelling reasons to choose 
the calves as an injection site and deemed this method of injection a 
therapeutic innovation rather than a negligent human experiment.211 
Further, the court reasoned that the radiologist was not negligent 
because he was trying to prevent the harm he had read about in journals 
by choosing an injection site further away from the sciatic nerve.212 
Additionally, the radiologist had used the injection site on other pediatric 
patients in the past with no adverse reactions.213 The court warned that 
“[t]oo often [other] courts have confused judgmental decisions and 
experimentation. Therapeutic innovation has long been recognized as 
permissible to avoid serious consequences.”214 Doctors should be 
presumed to have the knowledge and skills to make judgments necessary 
to treat their patients’ unique needs.215 The reasonable innovation rule 
permits physicians to innovate in a limited scope if the patient is not 
responding to customary care.216 
204.  Id. 
205.  Id. 
206.  Id. 
207.  Id. at 75. 
208.  Id. at 74. 
209.  Id. 
210.  Id. at 77. 
211.  Id. at 76. 
212.  Id. at 75. 
213.  Id. at 76. 
214.  Id. 
215.  Id. 
216.  Id. “(E)ven where there is an established mode of treatment, the physician may be 
permitted to innovate somewhat if he can establish that, in his best judgment, this was for the 
benefit of his patient and where the established modes of treatment have proved unsuccessful.” Id. 
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b. Felice v. Valleylab, Inc.
Felice v. Valleylab, Inc., by contrast, demonstrates that the 
reasonable innovation rule holds physicians accountable when they fail 
to follow reasonable practices. In that case, a two-year-old child 
complained of pain during urination.217 A physician diagnosed the child 
with phimosis218 and recommended a circumcision.219 Dr. Goodger, a 
first-year family practice resident, and Dr. Glass, a third-year surgery 
resident, were the only doctors present at the surgery.220 Dr. Glass 
instructed Dr. Goodger to perform the circumcision using the guillotine 
technique.221 Dr. Glass further instructed Dr. Goodger to use the 
Valleylab Electrosurgical Unit (“ESU”) to perform the procedure.222 
ESU “operates by applying a high frequency electrical current through a 
‘surgical pencil’ to the cutting area.”223 The doctors had cut one-third the 
distance across the foreskin when they realized something was wrong.224 
The child’s penis retracted and became very pale, and the doctors soon 
determined that he had sustained a full thickness burn225 from “excess 
electrical current running through the penis.”226 The physicians removed 
the remaining foreskin with scissors, sutured by hand, and applied burn 
cream to the child’s penis.227 Just a few days later, the child developed a 
high fever and was taken back to the hospital.228 When he arrived, 
at 76, n.1 
217.  Felice v. Valleylab, Inc., 520 So. 2d 920, 922 (La. Ct. App. 1987). 
 218.  “Phimosis is a constriction of the opening of the foreskin so that it cannot be drawn back 
over the tip of the penis. This condition is a normal occurrence in the newborn boy, but over time, 
the skin that adheres to the tip of the penis can be retracted as the foreskin loosens. By age 17, 99 
percent of males will be able to completely retract their foreskin.” Phimosis and Paraphimosis in 
Children, BOSTON CHILDREN’S HOSP., http://www.childrenshospital.org/health-topics/conditions/
p/phimosis-and-paraphimosis#sthash.9Q995J7v.dpuf (last visited Feb. 16, 2015). 
219.  Felice, 520 So. 2d at 922. 
220.  Id. at 923. 
221.  Id. “In this technique the foreskin of the penis is stretched past the end of the penis and 
clamped with a hemostat to hold the foreskin in a position to be cut off. After the excess foreskin is 
cut away, the bleeding is controlled and the edges of the foreskin are sutured together. Generally the 
cutting in circumcisions is performed with a scalpel.” Id. 
222.  Id. 
223.  Id. 
224.  Id. 
225.  Id. “A third-degree burn is referred to as a full thickness burn. This type of burn destroys 
the outer layer of skin (epidermis) and the entire layer beneath (or dermis).” Third Degree Burns, 
CHILDREN’S HOSP. OF WIS., http://www.chw.org/display/PPF/DocID/21911/router.asp (last visited 
Nov. 18, 2013). 
226.  Felice, 520 So. 2d at 923. 
227.  Id. 
228.  Id. 
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doctors discovered that his penis was completely gone.229 
The child’s parents sued the Department of Health and Human 
Resources, based on respondeat superior, as well as the hospital for 
negligent training and supervision.230 Valleylab was also named as a 
defendant for failure to warn of the dangers of the ESU device.231 The 
court found the state to be 100% at fault and awarded damages to the 
child and his family.232 The court reasoned that Dr. Glass was 
responsible for Dr. Goodger, but she simply assumed that Dr. Goodger 
had the requisite training and experience to perform a circumcision using 
the guillotine method with the ESU.233 
Dr. Glass admitted that she had never been trained to use an ESU to 
perform circumcisions in medical school, and in fact, she started using 
this method only one week prior to the child’s procedure.234 Dr. Glass 
had spoken with another resident about the possible benefits of a 
circumcision performed with an ESU, and then she had used that 
procedure on another patient with no adverse effects.235 The court noted 
that Dr. Glass did not inquire with her supervising doctors about the use 
of an ESU during circumcision.236 She did not read any medical 
literature or review the ESU manual for any warnings regarding using 
the device for circumcision.237 The patient did not even present a unique 
need that required a deviation from the standard practice for 
circumcision.238 Instead, “Dr. Glass merely decided to try it and see what 
effect the ESU would have upon the surgery, since she considered it an 
improvement upon well-established technique.”239 Because of these 
lapses in the standard of care expected in a procedure like this, and 
because Dr. Glass modified a familiar technique without adequately 
researching its potential adverse effects, the court found the state was 
vicariously responsible for her negligence.240 
229.  Id. 
230.  Id. 
231.  Id. 
232.  Id. at 929. 
233.  Id. at 928. 
234.  Id. 
235.  Id. 
236.  Id. 
237.  Id. 
238.  Id. at 929. 
239.  Id. at 928. 
240.  Id. at 928-29. “A hospital would be liable for the negligent act of a physician, nurse or 
any other ‘employee’ acting within the scope of his employment for the hospital under the doctrine 
of respondeat superior. In effect, the hospital is vicariously liable for the acts of its agent, servant or 
employee, whether he be physician, nurse, or technician where they have engaged in a negligent act 
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3. Comparing the Cases
Comparing these two cases illustrates the scope of the reasonable 
innovation rule. The Felice case is similar to the Brook case because 
both physicians deviated from the standard of care in their area.241 Both 
doctors believed they were improving on established techniques to 
enhance their patients’ care.242 The Felice case, however, radically 
differs from the Brook case because use of the ESU was not considered a 
reasonable innovation.243 In the Felice case, the patient did not present a 
unique need that required innovation and deviation from established 
standards of care.244 Furthermore, Dr. Glass failed to adequately research 
the procedure.245 She did not consult her supervising doctors and did not 
reference medical literature to explore potential consequences of what 
she thought was an innovative procedure.246 Additionally, she had 
performed the technique on only one other patient before deciding to 
implement the technique regularly.247 The gross deviation from 
customary care was a human experiment that left a boy permanently 
disfigured. The Brook case, on the other hand, illustrates the potential for 
appropriate innovation under the reasonable innovation rule: a doctor 
adequately researching and implementing an innovative, but reasonable, 
procedure based on a patient’s unique needs. 
The reasonable innovation rule is essential to medicine because we 
do not want to curb doctors’ new methods, ideas, and procedures, but we 
do want to protect the patient. Without innovation, the medical field 
would become stagnant, and we would not see the growth that 
innovation provides to the field.248 Each patient presents unique needs, 
and these needs can be met through reasonable innovation.249 
within the scope of their employment.” PEGALIS, supra note 2, § 6:20. 
 241.  See Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 77 (Ind. 1978); Felice, 520 
So. 2d at 928. 
242.  Brook, 380 N.E.2d at 74; Felice, 520 So. 2d at 928. 
243.  See Felice, 520 So. 2d at 928-29 (discussing reasonable innovation). 
244.  Id. at 929. 
245.  Id. at 928. 
246.  Id. 
247.  Id. at 928. 
248.  Philip D. Noguchi, From Jim to Gene and Beyond: An Odyssey of Biologics Regulation, 
51 FOOD & DRUG L.J. 367, 372 (1996). 
249.  Id. 
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F. Why the Reasonable Innovation Rule Should be Codified: 
Balancing the Interest of Innovation with the Protection of Patient 
Safety 
The reasonable innovation rule must be codified because it 
successfully balances the interests of the law, physicians, patients, and 
innovation. First, the law will benefit from codification because the rule 
will no longer be hidden in case law. If the FDA codifies this rule, it will 
be concrete and accessible as a regulation. Informed consent will no 
longer be the minimum standard. The shortcomings and problems with 
obtaining true informed consent will be addressed because the physician 
will assume a shared responsibility in the medical decision-making 
process. The physician will be held to a standard of implementing only 
reasonable innovations. Having a reasonable standard balances the 
physician’s interest in trying to save her patient by any means possible 
with what is reasonable based on the patient’s unique needs. 
Physicians will benefit from the codification of the reasonable 
innovation rule because their personal autonomy will be preserved. The 
rule is not so stringent as to eliminate freedom to deviate from common 
practices. It instead raises the minimum standard from being able to 
implement any procedure with informed consent to being able to 
implement any reasonable procedure. This will encourage researchers to 
focus on treatments that demonstrate success, like fecal transplants, 
while ensuring that physicians introduce only well-researched treatments 
to patients. Physicians will still find enjoyment and professional 
fulfillment in the latitude they are given in the decision-making process. 
Their knowledge, skills, training, and experience will be honored; their 
judgment, trusted. 
Patients will also benefit from codification of the rule. When 
patients are in a dire situation that makes them more likely to consent to 
dangerous novel treatments, the rule will provide an extra safeguard. The 
physician will be required to implement only what is reasonable, and 
patients can fully trust their doctor’s decisions. This will prevent results 
like those in the bacterial transplant case, where the physicians felt that 
they could side-step FDA regulations after obtaining their patients’ 
informed consent. Thus, the solidarity of the patient-physician 
relationship (which is already quite strong)250 will increase because the 
rule will foster trust. 
Finally, the interest of medical innovation and growth will be 
250.  Patient Consent, supra note 71. 
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preserved if the rule is codified. The rule recognizes that innovation is 
part of the medical profession and without innovation growth would be 
stunted. Innovative treatment based on the unique needs of the patient 
will still be permitted. This rule, however, will protect against 
unreasonable, poorly researched innovations not yet fit for human 
implementation regardless of whether patients have consented. 
G. Proposed Language for Codification 
The following language is proposed for codification: 
A physician may innovate if it is reasonable under the 
circumstances. The decision to innovate should be driven by the unique 
needs of the individual patient that cannot be met by customary practice. 
If the physician seeks to incorporate the innovation into daily practice 
involving all patients, the physician must first obtain permission from 
the IRB in the hospital where the innovative procedure will occur or, if 
the procedure will not occur in a hospital, a stand-alone IRB. 
Under this standard, the question of “reasonableness” is left to the 
jury to determine. Ideally, the jury will consider the same factors as in 
the Brook case: whether the doctor sufficiently researched the innovation 
by consulting professional literature prior to implementation , and 
whether there was evidence of prior success based on other patients. 
V. CONCLUSION 
Codification of the reasonable innovation rule will help avoid 
tragedies like the deaths of the three patients who consented to bacterial 
injections out of desperation. Under the proposed reasonable innovation 
rule, the patients’ consent would not have been enough to commence the 
procedure. Instead, the physician would have had an obligation to 
implement only what was reasonable based on extensive research. 
Implementing the reasonable innovation rule would have prevented the 
physicians from circumventing FDA protocol. It recognizes that even 
physicians may be blinded by their desire to do whatever possible to 
save their patients. While this desire is admirable, it demonstrates the 
need for a minimum standard in the decision-making process. 
The reasonable innovation rule will also foster innovation, as 
evidenced by the fecal transplant cases. This procedure, while not 
extensively studied in clinical trials, could be deemed reasonable based 
on the surrounding facts and evidence. The patients who underwent the 
fecal transplants presented a unique need that was not being met by 
customary practices. Novel innovations such as this are crucial, and the 
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rule will not curb the use of such treatments. Deeming an innovative 
treatment objectively reasonable is an important part of deciding 
whether to advise patients to undertake the potential risks of any given 
procedure. 
The FDA should codify the reasonable innovation rule because of 
these reasons. The medical and legal professions, as well as society as a 
whole, will greatly benefit from the rule’s codification. Most 
importantly, human experimentation masked as innovation will be 
reduced by codification of the rule. 
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